Order results by:
| Issue | Title | |
| Vol 15 (2023): (Suppl. 1) | Contribution of B-lymphocytes to the production of Interleukin-17 in multiple sclerosis | Abstract similar documents |
| N. V. Sursyakova, E. M. Kuklina, T. V. Baidina, I. V. Nekrasova, T. N. Trushnikova | ||
| "... The study of pathogenic systems involved in multiple sclerosis (MS) is essential ..." | ||
| Vol 12, No 1S (2020): Спецвыпуск: рассеянный склероз | Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... sclerosis (HAMS). After discussing the characteristics of action of the drug in clinical trials, the authors ..." | ||
| Vol 13, No 3 (2021) | Results of Expert Council meeting on modern principles of treatment optimization in patients with relapsing-remitting multiple sclerosis using anti-CD20 monoclonal antibody | Abstract similar documents |
| A. N. Boyko, N. V. Khachanova, D. S. Korobko, D. S. Kasatkin, Ya. V. Vlasov, E. P. Evdoshenko, E. V. Popova, K. Z. Bakhtiyarova, S. A. Sivertseva | ||
| "... sclerosis (MS). These cells play a significant role in immunoregulation in MS, not only by producing ..." | ||
| Vol 15 (2023): (Suppl. 1) | Prolonged observation after the use of cladribine in multiple sclerosis: efficacy and safety | Abstract similar documents |
| A. D. Kukushkina, A. N. Boyko | ||
| "... Multiple sclerosis (MS) is a chronic disease whose pathogenesis is based on autoimmune ..." | ||
| Vol 10, No 1 (2018) | New drugs for anti-B-cell therapy of multiple sclerosis | Abstract similar documents |
| A. N. Boyko, N. Yu. Lashch, M. E. Guseva | ||
| "... The review presents the data characterizing the mechanism of action of anti-B-cell therapy ..." | ||
| Vol 17, No 3 (2025) | Curcumin as add-on therapy in patients with multiple sclerosis showing a suboptimal response to first-line disease-modifying therapies: clinical outcomes and in vitro data | Abstract similar documents |
| A. D. Kukushkina, V. S. Rogovskii, E. V. Ponevezhskaia, E. V. Lysogorskaia, A. N. Boyko | ||
| "... In recent decades, pathogenetic therapy of multiple sclerosis (MS) has advanced significantly due ..." | ||
| Vol 11, No 1 (2019) | Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis | Abstract PDF (Eng) similar documents |
| O. V. Boyko, S. V. Petrov, N. Yu. Lashch, M. R. Guseva, A. N. Boyko | ||
| "... One of the promising areas in the pathogenetic treatment of multiple sclerosis (MS) is anti-B-cell ..." | ||
| Vol 17, No 3 (2025) | Switching from ocrelizumab to ofatumumab: key potential reasons based on real-world clinical practice | Abstract similar documents |
| A. N. Boyko, T. O. Simaniv, T. A. Prokopyeva, S. V. Petrov, M. V. Melnikov | ||
| "... In everyday neurological practice, B-cell-depleting therapies are playing an increasingly ..." | ||
| Vol 12, No 1 (2020) | Association of BAFF gene polymorphisms with multiple sclerosis progression | Abstract PDF (Eng) similar documents |
| I. V. Smagina, S. A. Elchaninova, A. S. Palashchenko | ||
| "... The cytokine of the tumor necrosis factor (TNF) family B-cell activating factor (BAFF) (TNFSF13B ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Reduced expression of the tumor necrosis factor gene in blood mononuclear cells in radiologically isolated syndrome – validation of transcriptome analysis results | Abstract similar documents |
| M. S. Kozin, N. M. Baulina, I. S. Kiselev, A. R. Kabaeva, A. N. Boyko, O. O. Favorova, O. G. Kulakova | ||
| "... sclerosis (MS) in individuals in the absence of clinical symptoms of the disease. Among the studies devoted ..." | ||
| Vol 16 (2024): (Suppl. 2) | Global transcriptome profiling of blood mononuclear cells from individuals with radiologically isolated syndrome reveals abnormalities characteristic of the rapid manifestation of multiple sclerosis symptoms | Abstract similar documents |
| M. S. Kozin, A. R. Kabaeva, M. A. Omarova, A. N. Boyko, O. O. Favorova, O. G. Kulakova | ||
| "... Objective: to look for differences in the transcriptome profiles in mononuclear blood cells ..." | ||
| Vol 16 (2024): (Suppl. 2) | Optimization of therapy in secondary progressive multiple sclerosis | Abstract similar documents |
| A. N. Boyko, S. K. Zyryanov, Ya. V. Vlasov | ||
| "... sclerosis (SPMS). The only drug that has proven its effectiveness in all types of SPMS (with exacerbations ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Clinical and epidemiological characteristics of multiple sclerosis in students in the Republic of Bashkortostan | Abstract similar documents |
| A. V. Tukhvatullin, U. Sh. Kuzmina, N. F. Utyagulova, R. F. Talisov, V. A. Vakhitov, K. Z. Bakhtiyarova | ||
| "... An expansion of the age range of multiple sclerosis (MS) manifestation has been reported recently ..." | ||
| Vol 11, No 4 (2019) | New possibilities for the therapy of secondary progressive multiple sclerosis | Abstract similar documents |
| A. M. Petrov, E. V. Ivashkova, I. D. Stolyarov | ||
| "... Patients with multiple sclerosis (MS) are at high risk for transition to secondary progressive MS ..." | ||
| Vol 16 (2024): (Suppl. 2) | Results of tele-rehabilitation in patients with multiple sclerosis during 2020–2021 COVID-19 pandemic | Abstract similar documents |
| S. A. Sivertseva, K. S. Anfilofeva, A. V. Zotova, V. D. Chukreev, A. Yu. Belkina, L. I. Volkova, M. E. Guseva, A. N. Boyko | ||
| "... Multiple sclerosis (MS) is a chronic autoimmune disease of the nervous system of a predominantly ..." | ||
| Vol 13, No 1 (2021) | New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis | Abstract similar documents |
| D. S. Kasatkin, N. V. Khachanova, V. M. Alifirova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, M. V. Davydovskaya, E. P. Evdoshenko, S. A. Sivertseva | ||
| "... The process of neurodegeneration in multiple sclerosis (MS) remains an urgent problem of modern ..." | ||
| Vol 8, No 2 (2016) | Histological classification of mesial temporal sclerosis | Abstract similar documents |
| D. V. Dmitrenko, M. A. Stroganova, N. A. Shnaider, G. P. Martynova, K. A. Gazenkampf, A. V. Dyuzhakova, Yu. S. Panina | ||
| "... Mesial temporal sclerosis (MTS) is the most common histopathology occurring in patients with drug ..." | ||
| Vol 15, No 6 (2023) | «Gut-brain» axis and multiple sclerosis | Abstract similar documents |
| M. A. Omarova, A. N. Boyko | ||
| "... An increase in the incidence of multiple sclerosis (MS) has been reported over the last decade ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Mechanisms of brain protection against autoimmune inflammation | Abstract similar documents |
| A. I. Volkov, M. V. Melnikov, A. N. Boyko | ||
| "... and circulation of antigen-presenting cells in the CNS. Moreover, the interaction of the CNS with the peripheral ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Influence of von Willebrand factor on common pathophysiological mechanisms of cerebrovascular diseases and multiple sclerosis | Abstract similar documents |
| I. A. Koltsov, M. Yu. Martynov, A. N. Yasamanova, I. A. Shchukin, M. S. Fidler, A. N. Boyko | ||
| "... to the development/progression of many diseases, including cerebrovascular disease and multiple sclerosis. Von ..." | ||
| Vol 15 (2023): (Suppl. 1) | The evolution of interferon therapy in multiple sclerosis | Abstract similar documents |
| O. V. Boyko, N. F. Smirnova, A. N. Boyko | ||
| "... The article reviews the evolution of interferon-β (IFN-β) in the treatment of multiple sclerosis ..." | ||
| Vol 16 (2024): (Suppl. 2) | Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres | Abstract similar documents |
| A. N. Boyko, V. M. Alifirova, D. V. Pashkovskaya, E. I. Kuchina, S. A. Sivertseva, E. L. Turova, Z. A. Goncharova, O. Yu. Rudenko, Yu. Yu. Pogrebnova, F. A. Khabirov, T. I. Khaibullin, N. N. Babicheva, N. L. Khoroshilova, O. V. Dzundza, O. A. Soldatova, A. N. Belova, G. Е. Sheiko, A. Е. Makarova, N. G. Glavinskaya | ||
| "... Multiple sclerosis (MS) is an autoimmune-inflammatory and neurodegenerative disease of the central ..." | ||
| Vol 16, No 5 (2024) | Efficacy and safety of cladribine tablets in multiple sclerosis in real-world clinical practice | Abstract similar documents |
| A. N. Peshkin, S. V. Kotov, G. T. Toniya, M. V. Sutormin, A. F. Eltayoury | ||
| "... . Objective: to determine the efficacy and safety of cladribine in the treatment of multiple sclerosis (MS ..." | ||
| Vol 11, No 4 (2019) | Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis | Abstract similar documents |
| A. N. Boyko, N. N. Spirin, Ya. V. Vlasov, M. N. Zakharova | ||
| "... More than 10 multiple sclerosis-modifying drugs (MSMDs) are widely used now. Novel MSMDs should ..." | ||
| Vol 13, No 6 (2021) | Changes in retinal structures as markers of multiple sclerosis progression | Abstract similar documents |
| M. O. Poplyak, A. G. Trufanov, A. V. Temniy, D. S. Maltsev, O. B. Chakchir, A. V. Mikheev, D. I. Skulyabin, G. N. Bisaga, I. V. Litvinenko, M. M. Odinak | ||
| "... The involvement of the visual pathway in multiple sclerosis (MS) pathology determines ..." | ||
| Vol 15 (2023): (Suppl. 1) | The place of virtual reality in the rehabilitation of patients with multiple sclerosis | Abstract similar documents |
| Iu. E. Korzhova, A. A. Fuks, A. S. Klochkov, A. E. Khizhnikova, N. A. Suponeva, M. N. Zakharova | ||
| "... Multiple sclerosis (MS) is a chronic autoimmune disease that limits the ability to work and lead ..." | ||
| Vol 16 (2024): (Suppl. 2) | Curcumin as an add-on therapy for multiple sclerosis in patients receiving interferon-beta therapy | Abstract similar documents |
| A. D. Kukushkina, V. S. Rogovskii, E. V. Ponevezhskaya, E. V. Lysogorskaia, A. N. Boyko | ||
| "... Search for agents for the add-on therapy of multiple sclerosis (MS) that can enhance the effect ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia | Abstract similar documents |
| A. N. Boiko, K. Z. Bakhtiyarova, M. A. Sherman, Z. A. Goncharova, I. V. Smagina, T. I. Khaibullin, N. N. Babicheva, N. N. Spirina, I. A. Yampolskaya-Gosteva, I. A. Sokolova, I. V. Greshnova, V. E. Nikitenkova, I. G. Lukashevich, A. V. Inzhinova, N. A. Malkova, D. S. Korobko, O. V. Boyko, I. S. Lozovskaya | ||
| "... Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative ..." | ||
| Vol 16 (2024): (Suppl. 2) | Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis | Abstract similar documents |
| F. A. Khabirov, E. V. Granatov, A. Ya. Dykhanov, T. I. Khaibullin | ||
| "... administration, which has moderate efficacy in reducing clinical exacerbations of multiple sclerosis (MS), which ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a) | Abstract similar documents |
| A. N. Boyko | ||
| "... Patient adherence to therapy with multiple sclerosis disease-modifying treatments (MS DMTs ..." | ||
| Vol 15 (2023): (Suppl. 1) | Prospects for the use of curcumin as an additional treatment for multiple sclerosis | Abstract similar documents |
| V. S. Rogovskii, A. D. Kukushkina, A. N. Boyko | ||
| "... Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease. MS therapy does not always ..." | ||
| Vol 15 (2023): (Suppl. 1) | MicroRNAs as biomarkers of multiple sclerosis progression | Abstract similar documents |
| N. M. Baulina, I. S. Kiselev, O. G. Kulakova, E. V. Popova, O. O. Favorova, A. N. Boyko | ||
| "... Multiple sclerosis (MS) is an autoimmune inflammatory neurodegenerative disease of the central ..." | ||
| Vol 14, No 1 (2022) | Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... reconstitution of highly active multiple sclerosis (HAMS) in general clinical practice. Patients and methods. 34 ..." | ||
| Vol 12, No 3 (2020) | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis | Abstract similar documents |
| K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, F. A. Khabirov, M. V. Shumilina | ||
| "... Currently, special attention is paid to timely treatment for active forms of multiple sclerosis ..." | ||
| Online-first | The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series | Abstract similar documents |
| E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko | ||
| "... In recent years, the incidence of multiple sclerosis (MS) has increased in the pediatric ..." | ||
| Vol 17, No 1 (2025) | The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series | Abstract similar documents |
| E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko | ||
| "... In recent years, the incidence of multiple sclerosis (MS) has increased in the pediatric ..." | ||
| Vol 7, No 1 (2015) | Time course of changes in the development of gait disorders in multiple sclerosis | Abstract similar documents |
| A. M. Petrov, I. D. Stolyarov, G. G. Shkilnyuk, A. G. Ilves, K. K. Mineev, V. V. Lebedev, T. L. Tsvetkova | ||
| "... sclerosis (MS) progresses in patients with different degrees of disability compared to a control group ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Art therapy possibilities in the complex treatment of patients with multiple sclerosis | Abstract similar documents |
| M. E. Guseva, O. V. Matvievskaya, A. N. Boyko | ||
| "... -progressive multiple sclerosis (MS). Patients and methods. A group of 42 patients (5 men and 37 women, mean ..." | ||
| Vol 7, No 1S (2015): Special issue "Epilepsy" | Epilepsy in patients with multiple sclerosis: specific features of diagnosis and therapy | Abstract similar documents |
| Yu. A. Belova, T. I. Yaukushina, I. G. Rudakova, S. V. Kotov | ||
| "... Once the symptoms of multiple sclerosis (MS) occur, the risk of developing epilepsy within 5 years ..." | ||
| Vol 16, No 3 (2024) | Experience of cladribine tablets usage in the treatment of multiple sclerosis in the Multiple Sclerosis Centre of the Khanty-Mansi Autonomous Area — Yugra | Abstract similar documents |
| A. A. Sokolova, L. I. Anischenko, L. S. Zemlyanushin, E. A. Rubtsova | ||
| "... Cladribine is a tablet preparation for the treatment of relapsing-remitting multiple sclerosis ..." | ||
| Vol 11, No 3 (2019) | Early cognitive dysfunction as a marker for the poor course of multiple sclerosis: a prospective 12-year follow-up | Abstract similar documents |
| D. S. Kasatkin, S. S. Molchanova, N. N. Spirin | ||
| "... Owing to the advent of current methods for the prevention of exacerbations of multiple sclerosis ..." | ||
| Vol 8, No 1 (2016) | Multiple sclerosis-related fatigue and possibilities of its correction | Abstract similar documents |
| N. Yu. Lashch, A. N. Boiko | ||
| "... Multiple sclerosis (MS)-related fatigue is encountered in 75–92% of patients and it is one ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Clinical presentation and course of multiple sclerosis in patients with herpesvirus infection | Abstract similar documents |
| M. S. Gris, N. S. Baranova, N. N. Spirin, D. S. Kasatkin, D. V. Kiselev, E. G. Shipova | ||
| "... for multiple sclerosis (MS) in the presence of persistent herpesvirus infection (PHVI) remain poorly understood ..." | ||
| Vol 15, No 6 (2023) | Ofatumumab – the first fully human monoclonal antibody approved for the treatment of multiple sclerosis | Abstract similar documents |
| E. V. Popova | ||
| "... Currently, more than 15 molecules are already approved for the treatment of multiple sclerosis ..." | ||
| Vol 11, No 4 (2019) | Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» | Abstract similar documents |
| N. V. Khachanova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, E. P. Evdoshenko, S. A. Sivertseva, T. E. Schmidt, M. V. Shumilina | ||
| "... progressive multiple sclerosis (MS) (SPMS), clinical trials, and promising treatments for the progressive MS ..." | ||
| Vol 12, No 5 (2020) | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets | Abstract similar documents |
| N. A. Totolyan, V. M. Alifirova, K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. N. Zakharova, D. S. Kasatkin, S. V. Kotov, A. I. Nilov, S. A. Sivertseva, A. A. Sokolova, N. N. Spirin, F. A. Khabirov, D. Paradnika | ||
| "... The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly ..." | ||
| Vol 14, No 2 (2022) | Changes in expression of miRNAs from the DLK1-DIO3 locus are characteristic of relapsing-remitting multiple sclerosis regardless of the disease activity | Abstract similar documents |
| N. M. Baulina, A. R. Kabaeva, A. N. Boyko, O. O. Favorova | ||
| "... The role of miRNAs – small, regulatory, noncoding RNAs – in the multiple sclerosis (MS ..." | ||
| Vol 17, No 1 (2025) | Aggressive multiple sclerosis in the Republic of Bashkortostan | Abstract similar documents |
| K. Z. Bakhtiyarova, U. Sh. Kuzmina, O. V. Lyutov, I. D. Talipova, N. F. Akhmetgaleeva, T. R. Galiullin, M. A. Kutlubaev | ||
| "... Treatment of patients with aggressive multiple sclerosis (MS) characterized by severe progression ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Current ethical issues of clinical trials of drugs for the pathogenetic therapy of multiple sclerosis in the context of the COVID-19 pandemic | Abstract similar documents |
| E. V. Ivashkova, A. M. Petrov, M. V. Votintseva, I. D. Stolyarov | ||
| "... institutions in terms of research for new multiple sclerosis (MS) treatments. In this review we discuss ..." | ||
| Vol 15, No 6 (2023) | Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting | Abstract similar documents |
| A. N. Boyko, V. V. Vashchilin, O. V. Boyko, A. G. Bunyak, D. S. Kasatkin, D. S. Korobko, S. I. Kulikova, N. V. Mazgo, N. V. Makovskaya, S. A. Sivertseva, I. V. Smagina, T. N. Chernukha | ||
| "... of patients with multiple sclerosis” on the organization of medical care, diagnosis and treatment of multiple ..." | ||
| Vol 15, No 6 (2023) | MRI assessment of different types of chronic demyelinating lesions in patients with multiple sclerosis using quantitative susceptibility mapping (QSM) | Abstract similar documents |
| M. S. Matrosova, V. V. Bryukhov, E. V. Popova, G. N. Belskaya, M. V. Krotenkova | ||
| "... Histologically, chronic demyelinating lesions in multiple sclerosis (MS) have been shown ..." | ||
| Vol 8, No 2 (2016) | Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies | Abstract similar documents |
| N. Yu. Lashch, A. N. Boiko | ||
| "... Multiple sclerosis (MS) is a demyelinating disease of the CNS, which affects mainly young able ..." | ||
| Vol 7, No 1 (2015) | Non-biological complex drugs and their analogues in the pathogenetic therapy of multiple sclerosis: Issues of efficacy and safety in clinical use | Abstract similar documents |
| I. D. Stolyarov, A. M. Petrov, M. V. Votintseva, I. G. Nikiforova | ||
| "... of multiple sclerosis (MS) – glatiramer acetate (GA, Copaxone®, Teva) in large Russian MS centers ..." | ||
| Vol 17, No 3 (2025) | Multiple sclerosis associated with adalimumab: a case report and systematic review | Abstract similar documents |
| A. A. Tappakhov, T. Ya. Nikolaeva, N. Yu. Gorokhova, L. T. Okoneshnikova, A. N. Ylakhova, E. E. Konnikova | ||
| "... The role of medications as risk factors for the development of multiple sclerosis (MS) remains ..." | ||
| Vol 15 (2023): (Suppl. 1) | Distinctive parameters of gait in patients with multiple sclerosis, depending on the profile of its dysfunction | Abstract similar documents |
| S. A. Ryabov, A. N. Boyko | ||
| "... sclerosis (MS) that allow the most reliable discrimination of the dominant profile in functional systems ..." | ||
| Vol 6, No 2 (2014) | Predementia states and dementia in young people | Abstract similar documents |
| A.A. Smirnov, A.V. Gustov, S.V. Kopishinskaya, V.A. Antonova | ||
| "... in patients with neuroAIDS, Huntington’s disease, or multiple sclerosis. ..." | ||
| Vol 8, No 4 (2016) | GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS | Abstract similar documents |
| T. E. Shmidt | ||
| "... Multiple sclerosis (MS) is the most common and potentially disabling disease of the central ..." | ||
| Vol 16 (2024): (Suppl. 2) | Sampeginterferon beta-1a in clinical practice | Abstract similar documents |
| I. A. Sokolova, O. S. Kornakova, E. V. Sokolova | ||
| "... In multiple sclerosis (MS), the development and introduction of disease-modifying treatments (DMTs ..." | ||
| Vol 8, No 3 (2016) | Cardiointervalography in patients with multiple sclerosis | Abstract similar documents |
| A. R. Rakhmatullin, K. Z. Bakhtiyarova, R. V. Magzhanov | ||
| "... sclerosis (MR) and, in some cases, pose a threat to their life. Objective: to study cardiovascular ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Attitude to reproduced disease modifying therapies in patients with relapsing-remitting multiple sclerosis: results of a medical and sociological study | Abstract similar documents |
| Ya. V. Vlasov, M. V. Churakov, E. V. Sineok, A. N. Boyko | ||
| "... The problem of an adequate choice of a treatment method in multiple sclerosis (MS) remains one ..." | ||
| Vol 4, No 2 (2012) | Clinical characteristics of multiple sclerosis in the Tomsk region | Abstract similar documents |
| V M Alifirova, M A Titova | ||
| "... sclerosis (MS) were examined to study its clinical picture in the Tomsk Region. There was a preponderance ..." | ||
| Vol 10, No 3 (2018) | Balo's concentric sclerosis: a clinical case | Abstract PDF (Eng) similar documents |
| I. V. Litvinenko, G. N. Bisaga, V. S. Chirsky, R. F. Gimadutdinov, P. S. Dynin, S. Yu. Golokhvastov, V. Yu. Lobzin | ||
| "... This paper describes a case of Balo's concentric sclerosis, a rare demyelinating disease ..." | ||
| Vol 16, No 3 (2024) | Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons | Abstract similar documents |
| K. V. Shevtsova, D. O. Rozhkov, D. A. Grishina, V. V. Grinyuk, V. V. Zakharov, N. M. Kashakanova, N. N. Koberskaya, O. V. Kosivtsova, A. B. Lokshina, Yu. A. Starchina, A. Yu. Tyurina, A. Yu. Fedorova, V. A. Parfenov | ||
| "... and indicated hippocampal sclerosis and tauopathy. At present, an accurate diagnosis of AD based on the study ..." | ||
| Vol 8, No 3 (2016) | Epidemiology of multiple sclerosis in the Bryansk Region | Abstract similar documents |
| Yu. N. Yurchenko, A. N. Yurchenko, I. V. Smagina | ||
| "... Objective: to study the clinical and epidemiological features of multiple sclerosis (MS ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Rehabilitation of patients with progressive forms of multiple sclerosis | Abstract similar documents |
| S. A. Sivertseva, K. S. Anfilofyeva, A. V. Zotova, A. A. Belkin, M. A. Sherman | ||
| "... sclerosis (MS). Currently, active research is being carried out in the field of telerehabilitation, extended ..." | ||
| Vol 12, No 1S (2020): Спецвыпуск: рассеянный склероз | Parent-child relationship and family system characteristics in families of adolescents with multiple sclerosis | Abstract similar documents |
| E. A. Boyko, E. V. Ivanchuk, K. R. Latii, V. L. Malygin, O. V. Bykova, T. T. Batysheva | ||
| "... The incidence of multiple sclerosis (MS) is increasing in all age groups, including children ..." | ||
| Vol 10, No 4 (2018) | Environmental factors and a risk for multiple sclerosis in the Altai Territory | Abstract similar documents |
| I. P. Saldan, I. V. Smagina, S. A. Elchaninova | ||
| "... Multiple sclerosis (MS) is a chronic dysimmune neurodegenerative disease of the central nervous ..." | ||
| Vol 12, No 1S (2020): Спецвыпуск: рассеянный склероз | The central vein sign in the differential diagnosis of multiple sclerosis | Abstract similar documents |
| S. E. Belov, A. N. Boyko | ||
| "... The current diagnosis of multiple sclerosis (MS) is based on confirmation of the disseminated ..." | ||
| Vol 9, No 1 (2017) | Clinical and epidemiological features of patients with multiple sclerosis in the Kursk Region | Abstract similar documents |
| V. B. Laskov, E. A. Logacheva, E. E. Tretyakova, M. A. Gridnev | ||
| "... Objective: to analyze the regional register of patients with multiple sclerosis (MS) in the Kursk ..." | ||
| Vol 15, No 3 (2023) | Impact of depression on the quality of life of patients with multiple sclerosis | Abstract similar documents |
| N. V. Zarubina, N. N. Spirin | ||
| "... Multiple sclerosis (MS) is a neurodegenerative disease that leads to multiple focal and diffuse ..." | ||
| 1 - 70 of 885 Items | 1 2 3 4 5 6 7 8 9 10 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
